<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p66" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_66{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_66{left:341px;bottom:30px;}
#t3_66{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_66{left:377px;bottom:30px;}
#t5_66{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_66{left:540px;bottom:30px;}
#t7_66{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_66{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_66{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_66{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_66{left:285px;bottom:827px;letter-spacing:-0.36px;word-spacing:0.11px;}
#tc_66{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_66{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_66{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_66{left:1112px;bottom:28px;letter-spacing:0.35px;}
#tg_66{left:36px;bottom:215px;}
#th_66{left:46px;bottom:209px;letter-spacing:0.08px;word-spacing:-0.01px;}
#ti_66{left:377px;bottom:209px;letter-spacing:0.12px;}
#tj_66{left:407px;bottom:209px;letter-spacing:0.13px;}
#tk_66{left:481px;bottom:209px;}
#tl_66{left:36px;bottom:198px;}
#tm_66{left:46px;bottom:192px;letter-spacing:0.12px;}
#tn_66{left:45px;bottom:176px;letter-spacing:0.12px;}
#to_66{left:36px;bottom:165px;}
#tp_66{left:46px;bottom:159px;letter-spacing:0.1px;word-spacing:0.02px;}
#tq_66{left:45px;bottom:142px;letter-spacing:0.12px;}
#tr_66{left:45px;bottom:125px;letter-spacing:0.11px;word-spacing:-0.06px;}
#ts_66{left:45px;bottom:108px;letter-spacing:0.12px;}
#tt_66{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#tu_66{left:765px;bottom:786px;}
#tv_66{left:36px;bottom:748px;letter-spacing:-0.1px;}
#tw_66{left:36px;bottom:729px;letter-spacing:-0.09px;word-spacing:-0.62px;}
#tx_66{left:36px;bottom:711px;letter-spacing:-0.1px;}
#ty_66{left:41px;bottom:693px;}
#tz_66{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t10_66{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t11_66{left:58px;bottom:656px;letter-spacing:-0.09px;}
#t12_66{left:63px;bottom:638px;}
#t13_66{left:76px;bottom:638px;letter-spacing:-0.09px;}
#t14_66{left:77px;bottom:619px;letter-spacing:-0.25px;word-spacing:0.01px;}
#t15_66{left:91px;bottom:601px;letter-spacing:-0.1px;}
#t16_66{left:322px;bottom:608px;letter-spacing:-0.12px;}
#t17_66{left:77px;bottom:583px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t18_66{left:92px;bottom:564px;}
#t19_66{left:103px;bottom:564px;letter-spacing:-0.09px;}
#t1a_66{left:103px;bottom:546px;letter-spacing:-0.09px;}
#t1b_66{left:103px;bottom:528px;letter-spacing:-0.1px;}
#t1c_66{left:92px;bottom:509px;}
#t1d_66{left:103px;bottom:509px;letter-spacing:-0.09px;}
#t1e_66{left:77px;bottom:491px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1f_66{left:91px;bottom:473px;letter-spacing:-0.08px;}
#t1g_66{left:41px;bottom:454px;}
#t1h_66{left:58px;bottom:454px;letter-spacing:-0.09px;}
#t1i_66{left:63px;bottom:436px;}
#t1j_66{left:76px;bottom:436px;letter-spacing:-0.09px;}
#t1k_66{left:547px;bottom:443px;letter-spacing:-0.12px;}
#t1l_66{left:36px;bottom:411px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t1m_66{left:378px;bottom:418px;}
#t1n_66{left:36px;bottom:392px;letter-spacing:-0.1px;}
#t1o_66{left:41px;bottom:374px;}
#t1p_66{left:58px;bottom:374px;letter-spacing:-0.14px;word-spacing:0.05px;}
#t1q_66{left:58px;bottom:356px;letter-spacing:-0.09px;}
#t1r_66{left:484px;bottom:363px;}
#t1s_66{left:41px;bottom:337px;}
#t1t_66{left:58px;bottom:337px;letter-spacing:-0.09px;}
#t1u_66{left:58px;bottom:319px;letter-spacing:-0.09px;}
#t1v_66{left:219px;bottom:327px;letter-spacing:-0.09px;}
#t1w_66{left:614px;bottom:748px;letter-spacing:-0.24px;}
#t1x_66{left:614px;bottom:729px;letter-spacing:-0.1px;}
#t1y_66{left:929px;bottom:737px;}
#t1z_66{left:614px;bottom:711px;}
#t20_66{left:624px;bottom:711px;letter-spacing:-0.43px;}
#t21_66{left:614px;bottom:693px;letter-spacing:-0.1px;}
#t22_66{left:620px;bottom:674px;}
#t23_66{left:636px;bottom:674px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#t24_66{left:636px;bottom:656px;letter-spacing:-0.09px;}
#t25_66{left:786px;bottom:656px;letter-spacing:-0.11px;}
#t26_66{left:843px;bottom:656px;}
#t27_66{left:642px;bottom:638px;}
#t28_66{left:655px;bottom:638px;letter-spacing:-0.09px;}
#t29_66{left:655px;bottom:619px;letter-spacing:-0.1px;}
#t2a_66{left:752px;bottom:627px;}
#t2b_66{left:620px;bottom:601px;}
#t2c_66{left:636px;bottom:601px;letter-spacing:-0.09px;}
#t2d_66{left:642px;bottom:583px;}
#t2e_66{left:659px;bottom:583px;letter-spacing:-0.09px;}
#t2f_66{left:1130px;bottom:590px;letter-spacing:-0.12px;}
#t2g_66{left:575px;bottom:232px;}
#t2h_66{left:585px;bottom:226px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2i_66{left:583px;bottom:209px;letter-spacing:0.13px;}
#t2j_66{left:575px;bottom:198px;}
#t2k_66{left:585px;bottom:192px;letter-spacing:0.11px;word-spacing:0.01px;}
#t2l_66{left:583px;bottom:176px;letter-spacing:0.09px;word-spacing:0.03px;}
#t2m_66{left:583px;bottom:159px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2n_66{left:583px;bottom:142px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2o_66{left:583px;bottom:125px;letter-spacing:0.11px;word-spacing:0.01px;}
#t2p_66{left:575px;bottom:114px;}
#t2q_66{left:585px;bottom:108px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2r_66{left:1095px;bottom:108px;}
#t2s_66{left:36px;bottom:280px;letter-spacing:-0.09px;}
#t2t_66{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_66{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_66{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_66{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_66{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_66{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_66{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_66{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_66{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_66{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_66{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_66{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_66{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_66{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_66{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_66{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sf_66{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts66" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg66Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg66" style="-webkit-user-select: none;"><object width="1210" height="935" data="66/66.svg" type="image/svg+xml" id="pdf66" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_66" class="t s0_66">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_66" class="t s1_66">® </span>
<span id="t3_66" class="t s0_66">(NCCN </span>
<span id="t4_66" class="t s1_66">® </span>
<span id="t5_66" class="t s0_66">), All rights reserved. NCCN Guidelines </span>
<span id="t6_66" class="t s1_66">® </span>
<span id="t7_66" class="t s0_66">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_66" class="t s2_66">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_66" class="t s2_66">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_66" class="t s3_66">NCCN Guidelines Version 4.2024 </span>
<span id="tb_66" class="t s3_66">Maxillary Sinus Tumors </span>
<span id="tc_66" class="t s4_66">NCCN Guidelines Index </span>
<span id="td_66" class="t s4_66">Table of Contents </span>
<span id="te_66" class="t s4_66">Discussion </span>
<span id="tf_66" class="t s5_66">MAXI-A </span>
<span id="tg_66" class="t s6_66">1 </span>
<span id="th_66" class="t s7_66">See Principles of Radiation Techniques (RAD-A) </span><span id="ti_66" class="t s8_66">and </span><span id="tj_66" class="t s7_66">Discussion</span><span id="tk_66" class="t s8_66">. </span>
<span id="tl_66" class="t s6_66">2 </span>
<span id="tm_66" class="t s8_66">In the paranasal sinus area, care should be taken to avoid critical neural </span>
<span id="tn_66" class="t s8_66">structures; therefore, 1.8 Gy/fraction can be considered. </span>
<span id="to_66" class="t s6_66">3 </span>
<span id="tp_66" class="t s8_66">For doses &gt;70 Gy, some clinicians feel that the fractionation should be </span>
<span id="tq_66" class="t s8_66">slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) </span>
<span id="tr_66" class="t s9_66">to minimize toxicity. An additional 2–3 doses can be added depending on </span>
<span id="ts_66" class="t s8_66">clinical circumstances. </span>
<span id="tt_66" class="t s5_66">PRINCIPLES OF RADIATION THERAPY </span>
<span id="tu_66" class="t sa_66">1 </span>
<span id="tv_66" class="t s5_66">DEFINITIVE: </span>
<span id="tw_66" class="t s5_66">RT Alone </span>
<span id="tx_66" class="t s5_66">• PTV </span>
<span id="ty_66" class="t sb_66"></span><span id="tz_66" class="t s5_66">High risk: Primary tumor and involved lymph nodes [this includes </span>
<span id="t10_66" class="t sc_66" data-mappings='[[29,"fi"]]'>possible local subclinical inﬁltration at the primary site and at the </span>
<span id="t11_66" class="t s5_66">high-risk level lymph node(s)] </span>
<span id="t12_66" class="t sd_66">◊ </span><span id="t13_66" class="t s5_66">Fractionation: </span>
<span id="t14_66" class="t s5_66">– 66 Gy (2.2 Gy/fraction) to 70–70.2 Gy (1.8–2.0 Gy/fraction) daily </span>
<span id="t15_66" class="t s5_66">Monday–Friday in 6–8 weeks </span>
<span id="t16_66" class="t sa_66">2,3 </span>
<span id="t17_66" class="t s5_66">– Concomitant boost accelerated RT: </span>
<span id="t18_66" class="t sc_66">▪ </span><span id="t19_66" class="t s5_66">72 Gy/6 weeks (2 Gy once daily and then 1.8 Gy/fraction, </span>
<span id="t1a_66" class="t sc_66" data-mappings='[[6,"fi"]]'>large ﬁeld; 1.5 Gy boost as second daily fraction during last </span>
<span id="t1b_66" class="t s5_66">12 treatment days) </span>
<span id="t1c_66" class="t sc_66">▪ </span><span id="t1d_66" class="t s5_66">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1e_66" class="t s5_66">– Hyperfractionation: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice </span>
<span id="t1f_66" class="t s5_66">daily) </span>
<span id="t1g_66" class="t sb_66"></span><span id="t1h_66" class="t s5_66">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1i_66" class="t sd_66">◊ </span><span id="t1j_66" class="t s5_66">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1k_66" class="t sa_66">4,5 </span>
<span id="t1l_66" class="t s5_66">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t1m_66" class="t sa_66">6 </span>
<span id="t1n_66" class="t s5_66">• PTV </span>
<span id="t1o_66" class="t sb_66"></span><span id="t1p_66" class="t s5_66">High risk: Typically 70–70.2 Gy </span>
<span id="t1q_66" class="t s5_66">(1.8–2.0 Gy/fraction); daily Monday–Friday in 7 weeks </span>
<span id="t1r_66" class="t sa_66">2 </span>
<span id="t1s_66" class="t sb_66"></span><span id="t1t_66" class="t s5_66">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy </span>
<span id="t1u_66" class="t s5_66">(1.6–1.8 Gy/fraction) </span>
<span id="t1v_66" class="t sa_66">4,5 </span>
<span id="t1w_66" class="t s5_66">POSTOPERATIVE: </span>
<span id="t1x_66" class="t s5_66">RT or Concurrent Systemic Therapy/RT </span>
<span id="t1y_66" class="t sa_66">6 </span>
<span id="t1z_66" class="t s5_66">• </span><span id="t20_66" class="t sc_66">Preferred interval between resection and postoperative RT is ≤6 weeks </span>
<span id="t21_66" class="t s5_66">• PTV </span>
<span id="t22_66" class="t sb_66"></span><span id="t23_66" class="t s5_66">High risk: Adverse pathologic features such as positive margins </span>
<span id="t24_66" class="t s5_66">(see footnote o on </span><span id="t25_66" class="t se_66">MAXI-3</span><span id="t26_66" class="t s5_66">) </span>
<span id="t27_66" class="t sd_66">◊ </span><span id="t28_66" class="t s5_66">60–66 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in </span>
<span id="t29_66" class="t s5_66">6–6.5 weeks </span>
<span id="t2a_66" class="t sa_66">2 </span>
<span id="t2b_66" class="t sb_66"></span><span id="t2c_66" class="t s5_66">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t2d_66" class="t sd_66">◊ </span><span id="t2e_66" class="t s5_66">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2f_66" class="t sa_66">4,5 </span>
<span id="t2g_66" class="t s6_66">4 </span>
<span id="t2h_66" class="t s8_66">Suggest 44–50 Gy in sequentially planned IMRT or 54–63 Gy with IMRT dose painting </span>
<span id="t2i_66" class="t s8_66">technique (dependent on dose per fraction). </span>
<span id="t2j_66" class="t s6_66">5 </span>
<span id="t2k_66" class="t s8_66">Treatment to sites of suspected subclinical spread is not consistently performed at all </span>
<span id="t2l_66" class="t s8_66">institutions (Le QT, Fu KK, Kaplan MJ, et al. Lymph node metastasis in maxillary sinus </span>
<span id="t2m_66" class="t s8_66">carcinoma. Int J Radiat Oncol Biol Phys 2000;46:541-549; and Jeremic B, Nguyen-Tan </span>
<span id="t2n_66" class="t s8_66">PF, Bamberg M. Elective neck irradiation in locally advanced squamous cell carcinoma </span>
<span id="t2o_66" class="t s8_66">of the maxillary sinus: a review. J Cancer Res Clin Oncol 2002;128:235-238). </span>
<span id="t2p_66" class="t s6_66">6 </span>
<span id="t2q_66" class="t s7_66">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2r_66" class="t s8_66">. </span>
<span id="t2s_66" class="t s5_66">Either IMRT or proton therapy is recommended for maxillary sinus or paranasal/ethmoid sinus tumors to minimize dose to critical structures. </span>
<span id="t2t_66" class="t sf_66">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
